Blocking γ-secretase pathways (e.g., Tarenflurbil [23], Semagacestat [22], Avagacestat [155]) is another approach in decreasing APP proteolysis followed by Aβ production, but they were not able to improve cognitive functions of AD brains neither [23]. The gene discussed is APP; the disease is Alzheimer disease.